IRIS
PALMIERI, RAFFAELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.006
AS - Asia 1.485
EU - Europa 1.375
SA - Sud America 256
AF - Africa 32
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 3
Totale 6.164
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.936
IT - Italia 704
SG - Singapore 655
CN - Cina 212
BR - Brasile 198
RU - Federazione Russa 186
HK - Hong Kong 174
VN - Vietnam 121
BD - Bangladesh 98
IE - Irlanda 93
DE - Germania 64
NL - Olanda 62
JP - Giappone 60
GB - Regno Unito 50
FR - Francia 49
CA - Canada 44
IN - India 43
FI - Finlandia 42
ID - Indonesia 23
PL - Polonia 21
AR - Argentina 20
SE - Svezia 19
MX - Messico 18
ES - Italia 17
KR - Corea 15
TH - Thailandia 13
AT - Austria 11
CO - Colombia 11
ZA - Sudafrica 11
BE - Belgio 10
IQ - Iraq 10
PH - Filippine 9
PK - Pakistan 9
VE - Venezuela 8
IR - Iran 7
SA - Arabia Saudita 7
AU - Australia 6
CZ - Repubblica Ceca 6
TR - Turchia 6
UA - Ucraina 6
EC - Ecuador 5
PY - Paraguay 5
GR - Grecia 4
HR - Croazia 4
KE - Kenya 4
MY - Malesia 4
RS - Serbia 4
SK - Slovacchia (Repubblica Slovacca) 4
TN - Tunisia 4
CL - Cile 3
DO - Repubblica Dominicana 3
EG - Egitto 3
LT - Lituania 3
LU - Lussemburgo 3
AE - Emirati Arabi Uniti 2
BO - Bolivia 2
CH - Svizzera 2
ET - Etiopia 2
GE - Georgia 2
IL - Israele 2
JM - Giamaica 2
MA - Marocco 2
NP - Nepal 2
PS - Palestinian Territory 2
RO - Romania 2
SD - Sudan 2
TW - Taiwan 2
UY - Uruguay 2
UZ - Uzbekistan 2
XK - ???statistics.table.value.countryCode.XK??? 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
BG - Bulgaria 1
BY - Bielorussia 1
CM - Camerun 1
CR - Costa Rica 1
DZ - Algeria 1
EE - Estonia 1
GA - Gabon 1
HU - Ungheria 1
JO - Giordania 1
KG - Kirghizistan 1
KW - Kuwait 1
KZ - Kazakistan 1
LB - Libano 1
LV - Lettonia 1
MK - Macedonia 1
NG - Nigeria 1
NI - Nicaragua 1
NZ - Nuova Zelanda 1
PE - Perù 1
PT - Portogallo 1
SI - Slovenia 1
SR - Suriname 1
TT - Trinidad e Tobago 1
Totale 6.164
Salva come PNG Salva come JPEG
Città #
Singapore 396
Houston 337
Wilmington 330
San Jose 219
Rome 203
Ashburn 169
Hong Kong 168
Chandler 153
New York 132
Council Bluffs 117
Beijing 101
Dallas 95
Fairfield 92
Los Angeles 72
Dublin 71
Santa Clara 60
Milan 56
Tokyo 56
Engelhard 49
Ho Chi Minh City 45
Woodbridge 43
Medford 41
The Dalles 40
Ann Arbor 37
Buffalo 37
Seattle 36
Cambridge 33
Boardman 32
Moscow 26
Lauterbourg 23
North Bergen 23
Lawrence 21
Orem 21
São Paulo 21
Lappeenranta 19
Hanoi 18
Warsaw 18
Brooklyn 17
Jakarta 17
San Diego 17
Helsinki 16
Bologna 15
Creede 15
Seoul 15
Montreal 14
Munich 14
Nuremberg 13
Chicago 12
Frankfurt am Main 12
Bang Bai Mai 11
Stockholm 11
Toronto 11
Amsterdam 10
Colorado Springs 10
London 10
Brussels 9
Turin 9
Bari 8
Billings 8
Redondo Beach 8
Atlanta 7
Bay Shore 7
Da Nang 7
Dearborn 7
Florence 7
Johannesburg 7
Phoenix 7
Baghdad 6
Charlotte 6
Mexico City 6
Porto Alegre 6
Pune 6
Rio de Janeiro 6
Shenzhen 6
Biên Hòa 5
Brno 5
Chennai 5
Denver 5
Haiphong 5
Hyderabad 5
Las Vegas 5
Marseille 5
Mumbai 5
Naples 5
Parma 5
Roebling 5
Tolentino 5
Washington 5
Asunción 4
Bari Sardo 4
Campinas 4
Castel Volturno 4
Columbus 4
Garbagnate Milanese 4
Guangzhou 4
Jeddah 4
Lahore 4
Manchester 4
Manila 4
Messina 4
Totale 3.901
Salva come PNG Salva come JPEG
Nome #
DIAGNOSTIC PERFORMANCE AND SAFETY OF BRONCHOALVEOLAR LAVAGE IN THROMBOCYTOPENIC HAEMATOLOGICAL PATIENTS FOR ASPERGILLOSIS DIAGNOSIS: A MONOCENTRIC, RETROSPECTIVE EXPERIENCE 385
Case report: A Saprochaete clavata (Magnusiomyces clavatus) severe infection effectively treated with granulocyte transfusion in a young patient with myeloid sarcoma 259
An evaluation of enasidenib for the treatment of acute myeloid leukemia 244
Clinical relevance of an objective - limit of detection - limit of quantification - based flow cytometry approach for measurable residual disease assessment in acute myeloid leukemia. A post-hoc analysis of the GIMEMA AML1310 trial 231
ACUTE LEUKEMIA AND LATENT TUBERCULOSIS INFECTION IN ITALY: QUANTIFERON-TB TEST SCREENING IN A LOW TUBERCULOSIS INCIDENCE COUNTRY 224
Therapeutic Choice in Older Patients with Acute Myeloid Leukemia: A Matter of Fitness 221
WT1 evaluation in higher-risk myelodysplastic syndrome patients treated with azacitidine 217
The Efficacy and Safety of Lenalidomide plus Rituximab in an Orbital Relapse of Diffuse Large B-Cell Lymphoma 199
Primary Cutaneous Anaplastic Large Cell Lymphoma of the Oral Cavity Successfully Treated with Brentuximab Vedotin 192
FEVER OF UNKNOWN ORIGIN AND MULTIDRUG-RESISTANT ORGANISMS COLONIZATION IN AML PATIENTS 155
Current strategies for detection and approach to measurable residual disease in Acute Myeloid Leukemia 149
Vitamin C Deficiency in Patients With Acute Myeloid Leukemia 147
ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol 143
Use of Measurable Residual Disease to Evolve Transplant Policy in Acute Myeloid Leukemia: A 20-Year Monocentric Observation 139
Use of Primary Prophylaxis with G-CSF in Acute Myeloid Leukemia Patients Undergoing Intensive Chemotherapy Does Not Affect Quality of Response 133
An Polycythemia Vera Evolve from Acute Myeloid Leukemia? Report of a Case Showing a Simultaneous Minor JAK2 V617F Mutated Clone 132
The ISTH DIC-score predicts early mortality in patients with non-promyelocitic acute myeloid leukemia 132
Baseline T-lymphocyte subset absolute counts can predict both outcome and severity in {SARS}-{CoV}-2 infected patients: a single center study 132
CD99 as a novel therapeutic target on leukemic progenitor cells in FLT3-ITDmut AML 131
A complex clinical presentation of ultra-high risk acute promyelocytic leukemia: A case report and insights on management 130
Acute Leukemia diagnosis during the Covid-19 pandemic 129
Validation of the T-Lymphocyte Subset Index (TLSI) as a Score to Predict Mortality in Unvaccinated Hospitalized COVID-19 Patients 107
Ponatinib and Risk of Thrombotic Events: In Vitro Study on Platelet Functions 107
CD34 + CD38-CLL1+ leukemic stem cells persistence measured by multiparametric flow cytometry is a biomarker of poor prognosis in adult patients with acute myeloid leukemia 104
Measurable Residual Disease (MRD) as a Surrogate Efficacy-Response Biomarker in AML 103
Comparison between azacitidine and decitabine as front-line therapy in elderly acute myeloid leukemia patients not eligible for intensive chemotherapy 102
Predictors of Early Thrombotic Events in Adult Patients with Acute Myeloid Leukemia: A Real-World Experience 98
A fatal case of peritonitis due to colonic localization of acute myeloid leukemia 93
Leukemia cutis in a patient with acute myeloid leukemia undergoing Azacitidine-Venetoclax: case presentation and review of the literature 90
Literature review and expert opinion on the treatment of high-risk acute myeloid leukemia in patients who are eligible for intensive chemotherapy 88
Impairment of FOXM1 expression in mesenchymal cells from patients with myeloid neoplasms, de novo and therapy-related, may compromise their ability to support hematopoiesis 86
Acute Myeloid Leukemia with Concomitant BCR-ABL and NPM1 Mutations 86
Pulmonary function testing for fitness assessment in asymptomatic adults with newly diagnosed acute myeloid leukemia 83
Pneumocystis jirovecii pneumonia in patients with previously untreated acute myeloid leukaemia 82
Optimal prognostic threshold for measurable residual disease positivity by multiparameter flow cytometry in acute myeloid leukemia (AML) 80
In BCR-ABL1 Positive B-Cell Acute Lymphoblastic Leukemia, Steroid Therapy Induces Hypofibrinogenemia 80
Evolution of transcriptomic profiles in relapsed inv(16) acute myeloid leukemia 79
THERAPY-RELATED MYELOID NEOPLASMS: CONSIDERATIONS FOR PATIENTS’ CLINICAL EVALUATION 78
The Venetoclax/Azacitidine Combination Targets the Disease Clone in Acute Myeloid Leukemia, Being Effective and Safe in a Patient with COVID-19 78
PML::RARα+ myeloid cells display metabolic alterations that can be targeted to treat resistant/relapse acute promyelocytic leukemias 73
Time for Dynamic Assessment of Fitness in Acute Myeloid Leukemia 71
Fitness in acute myeloid leukemia, state of the art and future directions 69
Impact of Time to Treatment Initiation on Quality of Response in Patients with Acute Myeloid Leukemia Receiving Intensive Chemotherapy 69
Editorial: Measurable residual disease in hematologic malignancies 64
Occult central nervous system involvement guides therapeutic choices in blastic plasmacytoid dendritic cell neoplasms 63
Real World Study on the Best CPX‐351 Treatment Duration and Timing for Allogeneic Stem Cell Transplantation 63
Risk-adapted MRD-directed therapy for young acute myeloid leukemia adults: 6-year update of the GIMEMA AML1310 trial 58
Associations Between Sex, Disease Features and Outcome in Patients With Acute Myeloid Leukemia: A Sex-Stratified Analysis of the GIMEMA AML1310 Trial 57
Increased Plasma Levels of lncRNAs LINC01268, GAS5 and MALAT1 Correlate with Negative Prognostic Factors in Myelofibrosis 55
FITNESS ASSESSMENT IN ACUTE MYELOID LEUKEMIA: RECOMMENDATIONS FROM AN EXPERT PANEL ON BEHALF OF EUROPEAN LEUKEMIA NET 52
Incidence and Characteristics of Perianal Infections in CPX-351-Treated AML Patients 51
Measurable residual disease as an actionable biomarker in acute myeloid leukemia. Ready or not? 48
The response to oxidative damage correlates with driver mutations and clinical outcome in patients with myelofibrosis 48
Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia 39
Prognostic relevance of limit of quantification as low-level cutoff for flow cytometry-based measurable residual disease assessment in acute myeloid leukemia 30
Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351 29
APL‐like subset within NPM1‐mutated AML: A distinct immunophenotype correlating with early vascular complications 20
The role of ponatinib in adult BCR-ABL1 positive acute lymphoblastic leukemia after allogeneic transplantation: a real-life retrospective multicenter study 13
Allogeneic stem cell transplantation in patients with a prior history of prostate cancer 13
Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML 13
Conditioning Intensity, Pre-Transplant Flow Cytometric Measurable Residual Disease, and Outcome in Adults with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation 11
Randomized phase 1 study of sequential ("primed") vs. concurrent decitabine in combination with cladribine, cytarabine, G-CSF, and mitoxantrone (CLAG-M) in adults with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) or other high-grade myeloid neoplasm 11
Health-related quality of life of patients with acute myeloid leukemia and myelodysplastic syndromes/neoplasms treated with decitabine: a systematic literature review 11
Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts 10
Accuracy of SIE/SIES/GITMO Consensus Criteria for Unfitness to Predict Early Mortality After Intensive Chemotherapy in Adults With AML or Other High-Grade Myeloid Neoplasm 10
Unbiased pro-thrombotic features at diagnosis in 977 thrombocythemic patients with Philadelphia-negative chronic myeloproliferative neoplasms 9
Totale 6.508
Salva come PNG Salva come JPEG
Categoria #
all - tutte 28.068
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 28.068
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202110 0 0 0 0 0 0 0 0 0 0 0 10
2021/2022325 4 11 13 3 9 45 16 17 52 31 20 104
2022/2023575 54 38 47 40 49 93 86 50 67 19 19 13
2023/2024532 26 8 168 9 20 103 17 45 30 16 20 70
2024/20251.239 48 168 114 75 25 78 132 62 195 113 138 91
2025/20262.910 238 127 324 241 335 107 301 318 277 285 202 155
Totale 6.508